Opinion
Video
Adverse Event Management: CRS and ICANS with Tarlatamab
Author(s):
Panelists discuss how the risks and clinical benefits of tarlatamab in relapsed or refractory extensive-stage small cell lung cancer must be carefully evaluated, considering the implications of bBlack bBox warnings for cytokine release syndrome and immune effector cell–-associated neurotoxicity syndrome, as well as the challenges of managing outpatient therapy for patients distant from treatment facilities, while also exploring the potential for reduced monitoring time between infusions given the safety profile observed in clinical studies.
Video content above is prompted by the following:
7. [All Faculty:] How do you weigh the risks vs clinical benefits of treatment with tarlatamab in relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC)?
- To what degree might a black box warning of the potential for developing cytokine release syndrome (CRS) or immune effector cell–associated neurotoxicity syndrome (ICANS) impact ready adoption of this new therapy by community oncologists for their patients with progressive ES-SCLC?
- When patients with ES-SCLC are managed in the community at a distance from a treating facility, how problematic is inpatient therapy or observation for their scheduled regimen?
- Given that no fatal CRS or ICANS events were reported with the 10-mg dose and only 1 dose interruption was reported in the published phase II study report, what is the potential to reduce patient monitoring time between bimonthly infusions of tarlatamab?
